Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis

By afschroeder • August 17, 2025

Pontolillo L, Davis AA, Gerratana L, Medford AJ, Wang J, Nicolo' E, Clifton K, Velimirovic M, Warrior S, Podany E, Andreopoulou E, Serafini MS, Munoz-Arcos L, Molteni E, Lipsyc-Sharf M, Gianni C, Bayou N, Dai CS, Giannarelli D, Bria E, Ma CX, Bardia A, Reduzzi C, Cristofanilli M. Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis. NPJ Breast Cancer. 2025 Aug 16;11(1):93. doi: 10.1038/s41523-025-00802-2. PMID: 40819062; PMCID: PMC12357851.

Tags: Hematology/Oncology, Publications

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

Kim YJ, Merle P, Finn RS, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Pinter M, Babajanyan S, Twumasi-Ankrah P, Ghadessi[...]

Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance

Markosian C, Buckley CW, Chai-Ho W, Schiller GJ. Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance. Leuk[...]

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer

Su Y, Liu C, Lu X, Chuang HY, Li G, Shao S, Kong Y, Lee JW, Ng RH, Wong S, Robert L, Warden C, Liu[...]